Ambit Biosciences Corp. was acquired by Daiichi Sankyo (TYO: 4568) in November of 2014. Prior to the acquisition, the company was focused on developing its lead drug candidate, Quizartinib, a once-daily, orally-administered kinase inhibitor initially targeting patients with relapsed/refractory acute myeloid leukemia, or AML. Ambit completed an IPO in May 2013.